Monday, November 21, 2011 9:56:19 AM
On Thursday last week, when PPD, Inc., a leading global contract research organization, gave a presentation relating to current issues in cardiac safety, and the impact it has on drug development, it was clearly a hot topic for many listeners involved in bringing new drugs to market. An informal poll taken during the online presentation indicated that over 90% of involved listeners felt that cardiac safety was a clear factor in the drug development process.
PPD is known for providing drug discovery, development, and life cycle management services for pharmaceutical and other companies, as well as for government organizations, and has offices in 44 countries around the world. The presentation was given by Rob Dow, VP of Strategic Product Development at PPD, and Robert Kleiman, MD, Chief Medical Officer and VP of Global Cardiology at ERT, an industry leader in cardiac safety drug research.
One of the points emphasized in the presentation was the fact that the U.S. Food and Drug Administration now requires cardiovascular outcomes evaluation for non-cardiovascular drugs in several therapeutic areas, all of which can significantly impact drug development. Today, so-called blockbuster drugs can lead to the exposure of millions of patients. Previous high-profile market withdrawals of FDA-approved drugs involving cardiovascular safety issues, and the associated public outcry, fueled major changes in what is required by drug developers to ensure cardiovascular safety. Given traditional testing methods, which are used late in the preclinical development process, it adds another layer of complexity and expense for drug developers.
The issue of cardiovascular safety for new drugs underlines the importance of VistaGen’s developments in clinically relevant cardiovascular toxicity testing before new drug candidates are ever tested in humans. Just when it is needed most, VistaGen’s Human Clinical Trials in a Test Tube platform, using advanced stem cell technology, is an important new tool for the pharmaceutical industry, allowing companies to accurately test for potential cardiovascular toxicity in the early preclinical stages of drug development, offering potential far-reaching savings in time and money. Instead of going through the tremendous investments necessary for developing a new drug, only to have it shot down in the last stages by unexpected cardiovascular toxicity issues, the risks can now be identified up front, and steps taken to rescue and re-engineer the drug candidate.
For additional information, visit the company’s website at www.VistaGen.com
Recent VTGN News
- Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year • Business Wire • 06/27/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:27:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/11/2024 08:27:09 PM
- Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update • Business Wire • 06/11/2024 08:20:00 PM
- U.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices Decline • IH Market News • 06/11/2024 11:07:13 AM
- Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 • Business Wire • 06/07/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:10:11 PM
- Vistagen to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:30:00 PM
- Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference • Business Wire • 05/23/2024 12:30:00 PM
- Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 12:30:00 PM
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue • Business Wire • 04/25/2024 12:30:00 PM
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference • Business Wire • 04/09/2024 12:30:00 PM
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 • Business Wire • 04/01/2024 12:30:00 PM
- Vistagen to Present at Stifel 2024 Virtual CNS Days • Business Wire • 03/11/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:10 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/01/2024 05:15:07 AM
- Vistagen to Present at TD Cowen 44th Annual Health Care Conference • Business Wire • 02/28/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:18:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:51:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:56:03 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/13/2024 09:52:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:33:59 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM